|
Summary
June 2008, Vol. 9, No. 8, Pages 1291-1298
, DOI 10.1517/14656566.9.8.1291
Antidepressant therapy in post-stroke depressionSergio E Starkstein1University of Western Australia, School of Psychiatry and Clinical Neurosciences, Australia 2Fremantle Hospital, Education Building T-7, Fremantle, 6959 WA, Australia +61 8 9431 2013; +61 8 9336 5505; ses@cyllene.uwa.edu.au 3University of Toronto, Toronto, Canada 4Center for Addiction and Mental Health, Clarke Division, Toronto, Canada Background: About 40% of patients with stroke will develop depression at some stage after the acute event. Post-stroke depression (PSD) is associated with a poor prognosis. Depressed patients have more severe deficits in activities of daily living, a worse functional outcome, more severe cognitive deficits and increased mortality as compared to stroke patients without depression. Objective: This review will focus on available controlled trials of treatment for PSD. Methods: An unsystematic review of recent studies for the treatment of PSD. Results: Randomized controlled trials have demonstrated the efficacy of sertraline, citalopram and nortriptyline to treat post-stroke depression. Whether antidepressant medication may help to prevent post-stroke depression and decrease post-stroke mortality will require further controlled studies. Users who read this article also read:
|
|





Author for correspondence
TOC Alert